Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model

Cancer Biology and Therapy

Volumn 14, Issue 4, 2013, Pages 357-364

  De Angel, Rebecca E ^a   Blando, Jorge M ^a   Hogan, Matthew G ^a   Sandoval, Michael A ^a   Lansakara P, Dharmika S P ^a   Dunlap, Sarah M ^b   Hursting, Stephen D ^b,c   Cui, Zhengrong ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b The University of Texas at Austin   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemoresistance; Nanoparticles; Obesity; Tumor

Indexed keywords

GEMCITABINE; NANOPARTICLE; WNT1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; DRUG EFFICACY; FEMALE; MOUSE; NONHUMAN; OBESITY; ORTHOTOPIC TRANSPLANTATION; OVARIECTOMY; POSTMENOPAUSE; TUMOR CELL;

CHEMORESISTANCE; NANOPARTICLES; OBESITY; TUMOR;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NANOPARTICLES; OBESITY; POSTMENOPAUSE; RANDOM ALLOCATION;

EID: 84875840423     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.23623     Document Type: Article

References (40)

1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348:1625-38; PMID:12711737; http://dx.doi.org/10.1056/ NEJMoa021423.
2. Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA. Body mass and mortality after breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev 2005; 14:2009-14; PMID:16103453; http://dx.doi.org/10.1158/1055- 9965.EPI-05-0106.
3. Pavelka JC, Brown RS, Karlan BY, Cass I, Leuchter RS, Lagasse LD, et al. Effect of obesity on survival in epithelial ovarian cancer. Cancer 2006; 107:1520-4; PMID:16941453; http://dx.doi.org/10.1002/cncr.22194.
4. Jain R, Chung SM, Jain L, Khurana M, Lau SW, Lee JE, et al. Implications of obesity for drug therapy: Limitations and challenges. Clin Pharmacol Ther 2011; 90:77-89; PMID:21633345; http://dx.doi.org/10.1038/clpt.2011.104.
5. Behan JW, Yun JP, Proektor MP, Ehsanipour EA, Arutyunyan A, Moses AS, et al. Adipocytes impair leukemia treatment in mice. Cancer Res 2009; 69:7867-74; PMID:19773440; http://dx.doi.org/10.1158/0008-5472.CAN-09-0800.
6. Hursting SD. Inflammatory talk: Linking obesity, NF-κB, and Aromatase. Cancer Prev Res (Phila) 2011; 4:285-7; PMID:21372024; http://dx.doi.org/10.1158/1940-6207.CAPR-11-0056.
7. Harvey AE, Lashinger LM, Hursting SD. The growing challenge of obesity and cancer: An inflammatory issue. Ann N Y Acad Sci 2011; 1229:45-52; PMID:21793838; http://dx.doi.org/10.1111/j.1749-6632.2011.06096.x.
8. Behan JW, Avramis VI, Yun JP, Louie SG, Mittelman SD. Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice. Pharmacol Res 2010; 61:385-90; PMID:20083201; http://dx.doi.org/10.1016/j.phrs. 2010.01.007.
9. Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) 2011; 4:329-46; PMID:21372033; http://dx.doi.org/10.1158/1940-6207.CAPR-10-0381.
10. Royer I, Monsarrat B, Sonnier M, Wright M, Cresteil T. Metabolism of docetaxel by human cytochromes P450: Interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996; 56:58-65; PMID:8548776.
11. Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: A systematic review. Obes Rev 2003; 4:157-73; PMID:12916817; http://dx.doi.org/10. 1046/j.1467-789X.2003.00108.x.
12. Cleary MP, Grossmann ME. Minireview: Obesity and breast cancer: The estrogen connection. Endocrinology 2009; 150:2537-42; PMID:19372199; http://dx.doi.org/10.1210/en.2009-0070.
13. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: Systematic review and meta-analysis. Breast Cancer Res Treat 2010; 123:627-35; PMID:20571870; http://dx.doi.org/10.1007/s10549-010-0990-0.
14. De Angel RE, Conti CJ, Wheatley KE, Brenner AJ, Otto G, Degraffenried LA, et al. The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001. Mol Carcinog 2012; PMID:22290600; http://dx.doi.org/10.1002/mc.21878.
15. Fuchs-Young R, Shirley SH, Lambertz I, Colby JK, Tian J, Johnston D, et al. P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis. Breast Cancer Res Treat 2011; 130:399-408; PMID:21191649; http://dx.doi.org/10.1007/s10549-010-1308-y.
16. Dunlap SM, Chiao LJ, Nogueira L, Usary J, Perou CM, Varticovski L, et al. Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basallike mammary tumor models. Cancer Prev Res (Phila) 2012; 5:930-42; PMID:22588949; http://dx.doi.org/10.1158/1940- 6207.CAPR-12-0034.
17. De Angel RE, Berrigan D, Núñez NP, Hursting SD, Perkins SN. Dietary calcium source influences body composition, glucose metabolism and hormone levels in a mouse model of postmenopausal obesity. In Vivo 2009; 23:527-35; PMID:19567386.
18. Núñez NP, Perkins SN, Smith NCP, Berrigan D, Berendes DM, Varticovski L, et al. Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr Cancer 2008; 60:534-41; PMID:18584488; http://dx.doi.org/10.1080/01635580801966195.
19. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010; 7:653-64; PMID:20838415; http://dx.doi.org/10.1038/ nrclinonc. 2010.139.
20. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008; 14:1310-6; PMID:18316549; http://dx.doi.org/10.1158/1078-0432.CCR-07-1441.
21. Blanco E, Hsiao A, Mann AP, Landry MG, Meric-Bernstam F, Ferrari M. Nanomedicine in cancer therapy: Innovative trends and prospects. Cancer Sci 2011; 102:1247-52; PMID:21447010; http://dx.doi.org/10.1111/j.1349-7006.2011. 01941.x.
22. Adair JH, Parette MP, Altinoǧlu EI, Kester M. Nanoparticulate alternatives for drug delivery. ACS Nano 2010; 4:4967-70; PMID:20873786; http://dx.doi.org/10.1021/nn102324e.
23. Cobleigh MA. Other options in the treatment of advanced breast cancer. Semin Oncol 2011; 38(Suppl 2):S11-6; PMID:21600380; http://dx.doi.org/10.1053/j. seminoncol.2011.04.005.
24. Sloat BR, Sandoval MA, Li D, Chung WG, Lansakara PDS, Proteau PJ, et al. In vitro and in vivo antitumor activities of a gemcitabine derivative carried by nanoparticles. Int J Pharm 2011; 409:278-88; PMID:21371545; http://dx.doi.org/10.1016/j. ijpharm.2011.02.037.
25. Chung WG, Sandoval MA, Sloat BR, Lansakara PDS, Cui Z. Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1. J Control Release 2012; 157:132-40; PMID:21851843; http://dx.doi.org/10.1016/j.jconrel.2011.08.004.
26. Lansakara PDS, Rodriguez BL, Cui Z. Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles. Int J Pharm 2012; 429:123-34; PMID:22425885; http://dx.doi.org/ 10.1016/j.ijpharm.2012.03.014.
27. Sandoval MA, Sloat BR, Lansakara PDS, Kumar A, Rodriguez BL, Kiguchi K, et al. EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity. J Control Release 2012; 157:287-96; PMID:21871505; http://dx.doi.org/10.1016/j. jconrel.2011.08.015.
28. Price RS, Cavazos DA, De Angel RE, Hursting SD, deGraffenried LA. Obesity-related systemic factors promote an invasive phenotype in prostate cancer cells. Prostate Cancer Prostatic Dis 2012; 15:135-43; PMID:22333686; http://dx.doi.org/10.1038/pcan.2011.54.
29. Núñez NP, Carpenter CL, Perkins SN, Berrigan D, Jaque SV, Ingles SA, et al. Extreme obesity reduces bone mineral density: Complementary evidence from mice and women. Obesity (Silver Spring) 2007; 15:1980-7; PMID:17712115; http://dx.doi.org/10.1038/oby.2007.236.
30. Calle EE, Kaaks R. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4:579-91; PMID:15286738; http://dx.doi.org/10.1038/nrc1408.
31. Griggs JJ, Sabel MS. Obesity and cancer treatment: Weighing the evidence. J Clin Oncol 2008; 26:4060-2; PMID:18757320; http://dx.doi.org/10.1200/JCO. 2008.17.4250.
32. Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 2007; 96:457-63; PMID:17224927; http://dx.doi.org/10.1038/sj.bjc.6603559.
33. Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, et al. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia 2010; 12:807-17; PMID:20927319.
34. Lozzi GP, Massone C, Citarella L, Kerl H, Cerroni L. Rimming of adipocytes by neoplastic lymphocytes: A histopathologic feature not restricted to subcutaneous T-cell lymphoma. Am J Dermatopathol 2006; 28:9-12; PMID:16456318; http://dx.doi.org/10.1097/01. dad.0000187933.87103.03.
35. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000; 39:215-31; PMID:11020136; http://dx.doi.org/ 10.2165/00003088-200039030-00004.
36. Navarro WH. Impact of obesity in the setting of high-dose chemotherapy. Bone Marrow Transplant 2003; 31:961-6; PMID:12774045; http://dx.doi.org/10.1038/ sj.bmt.1704052.
37. Shipley LA, Brown TJ, Cornpropst JD, Hamilton M, Daniels WD, Culp HW. Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos 1992; 20:849-55; PMID:1362937.
38. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41:189-207; PMID:11384745; http://dx.doi.org/10.1016/S0065- 2571(00)00013-3.
39. Veltkamp SA, Pluim D, van Eijndhoven MA, Bolijn MJ, Ong FH, Govindarajan R, et al. New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine. Mol Cancer Ther 2008; 7:2415-25; PMID:18723487; http://dx.doi.org/10.1158/1535-7163.MCT-08-0137.
40. Haslam SZ, Osuch JR, Raafat AM, Hofseth LJ. Postmenopausal hormone replacement therapy: Effects on normal mammary gland in humans and in a mouse postmenopausal model. J Mammary Gland Biol Neoplasia 2002; 7:93-105; PMID:12160089; http://dx.doi.org/10.1023/A:1015726608146.